$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Systemtherapie der Vitiligo : Bilanz und aktuelle Entwicklungen
Systemic treatment of vitiligo : Balance and current developments

Der Hautarzt : Zeitschrift für Dermatologie, Venerologie und verwandte Gebiete, v.68 no.11, 2017년, pp.876 - 884  

Meurer, M. ,  Ceric-Dehdari, P.

초록이 없습니다.

참고문헌 (58)

  1. JAMA Dermatol JM Bae 153 666 2017 10.1001/jamadermatol.2017.0002 Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, Kim GM (2017) Phototherapy for Vitiligo. A systematic review and met-analysis. JAMA Dermatol 153:666-674 

    상세보기 crossref

  2. J Invest Dermatol M Cavalié 135 970 2015 10.1038/jid.2014.527 Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, Taïeb A, Lacour JP, Passeron T (2015) Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol 135:970-974 

    상세보기 crossref

  3. Am J Clin Dermatol BE Cohen 16 463 2015 10.1007/s40257-015-0153-5 Cohen BE, Elbuluk N, Mu EW, Orlow SJ (2015) Alternative systemic treatments for Vitiligo: a review. Am J Clin Dermatol 16:463-474 

    상세보기 crossref

  4. J Invest Dermatol BG Craiglow 134 2988 2014 10.1038/jid.2014.260 Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134:2988-2990 

    상세보기 crossref

  5. JAMA Dermatol BG Craiglow 151 1110 2015 10.1001/jamadermatol.2015.1520 Craiglow BG, King BA (2015) Tofacitinib citrate for the treatment of Vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 151:1110-1112 

    crossref

  6. J Am Acad Dermatol W Damsky 76 736 2017 10.1016/j.jaad.2016.12.005 Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76:736-744 

    상세보기 crossref

  7. Clin Exp Dermatol ML Dell’Anna 32 631 2007 10.1111/j.1365-2230.2007.02514.x Dell’Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, Leone G, Calzavara PG, Westerhof W, Picardo M (2007) Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 32:631-636 

    상세보기 crossref

  8. Dermatol Ther M Mofty El 29 406 2016 10.1111/dth.12384 El Mofty M, Essmat S, Youssef R, Sobeih S, Mahgoub D, Ossama S, Saad A, El Tawdy A, Mashaly HM, Saney I, Helal R, Shaker O (2016) The role of systemic steroids and phototherapy in the treatment of stable vitiligo: a randomized controlled trial. Dermatol Ther 29:406-412 

    상세보기 crossref

  9. Pigment Cell Melanoma Res V Eleftheriadou 28 363 2015 10.1111/pcmr.12354 Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, de Silva de Castro CC, Pandya A, Goh BK, Lan CC, Oiso N, Al Issa A, Esmat S, Le Poole C, Lee AY, Parsad D, Taïeb A, Picardo M, Ezzedine K (2015) Developing core outcome set for vitiligo clinical trials: international e‑Delphi consensus. Pigment Cell Melanoma Res 28:363-369 

    상세보기 crossref

  10. Lancet K Ezzedine 386 74 2015 10.1016/S0140-6736(14)60763-7 Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (2015) Vitiligo. Lancet 386:74-84 

    상세보기 crossref

  11. J Allergy Clin Immunol M Frisoli 140 654 2017 10.1016/j.jaci.2017.07.011 Frisoli M, Harris JE (2017) Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol 140:654-662 

    상세보기 crossref

  12. J Invest Dermatol NB Goldstein 135 2068 2015 10.1038/jid.2015.126 Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA (2015) Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol 135:2068-2076 

    상세보기 crossref

  13. JAMA Dermatol PE Grimes 149 68 2013 10.1001/2013.jamadermatol.386 Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW (2013) The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol 149:68-73 

    상세보기 crossref

  14. Arch Dermatol AK Gupta 126 339 1990 10.1001/archderm.1990.01670270071012 Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, Griffiths CE, Cooper KD, Voorhees JJ (1990) Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 126:339-350 

    상세보기 crossref

  15. J Am Acad Dermatol JE Harris 74 370 2016 10.1016/j.jaad.2015.09.073 Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J (2016) Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata. J Am Acad Dermatol 74:370-371 

    상세보기 crossref

  16. J Invest Dermatol JE Harris 132 7 1869 2012 10.1038/jid.2011.463 Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T‑cell accumulation in the skin. J Invest Dermatol 132(7):1869-1876 

    상세보기 crossref

  17. J Investig Dermatol Symp Proc NK Haass 10 153 2005 10.1111/j.1087-0024.2005.200407.x Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigmfor understanding melanoma. J Investig Dermatol Symp Proc 10:153-163 

    상세보기 crossref

  18. Arch Dermatol I Hamzavi 140 677 2004 10.1001/archderm.140.6.677 Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H (2004) Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 140:677-683 

    상세보기 crossref

  19. N Engl J Med J Harms 360 306 2009 10.1056/NEJMc0805682 Harms J, Lautenschläger S, Minder CE, Minder EL (2009) An alpha-melanocyte-stimulating hormone analogue in erythropoetic protoporphyria. N Engl J Med 360:306-307 

    상세보기 crossref

  20. J Dtsch Dermatol Ges K Jahn-Bassler 15 42 2017 Jahn-Bassler K, Bauer WM, Karlhofer F, Vossen MG, Stingl G (2017) Kombinierte Hoch‑/Niedrig-Dosis-Therapie mit systemischen Glukokortikosteroiden bei schweren Verlaufsformen der Alopecia areate im Kindesalter. J Dtsch Dermatol Ges 15:42-48 

  21. Curr Opin Immunol K Hirahara 43 89 2016 10.1016/j.coi.2016.10.001 Hirahara K, Schwartz D, Gadina M, Kanno Y, O’Shea JJ (2016) Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol 43:89-97 

    상세보기 crossref

  22. J Clin Invest S Jamal 110 443 2002 10.1172/JCI0213729 Jamal S, Schneider RJ (2002) UV-induction of keratinocyte endothelin-1 downregulates E‑cadherin in melanocytes and melanoma cells. J Clin Invest 110:443-452 

    상세보기 crossref

  23. J Int Med Res N Karsli 42 799 2014 10.1177/0300060513516294 Karsli N, Akcali C, Ozgoztasi O, Kirtak N, Inaloz S (2014) Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy. J Int Med Res 42:799-805 

    상세보기 crossref

  24. J Am Acad Dermatol E Lilly 69 e11 2013 10.1016/j.jaad.2012.01.038 Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV (2013) Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 69:e11-e18 

    상세보기 crossref

  25. JAMA Dermatol HW Lim 151 42 2015 10.1001/jamadermatol.2014.1875 Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M (2015) Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 151:42-50 

    상세보기 crossref

  26. J Am Acad Dermatol LY Liu 77 675 2017 10.1016/j.jaad.2017.05.043 Liu LY, Strassner JP, Refat MA, Harris JE, King BA (2017) Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 77:675-682 

    상세보기 crossref

  27. Clin Exp Dermatol L Lu 41 1 64 2015 10.1111/ced.12664 Lu L, Wang S, Fu L, Liu D, Zhu Y, Xu A (2015) Bilobalide protection of normal human melanocytes from hydrogen peroxide-induced oxidative damage via promotion of antioxidase expression and inhibition of endoplasmic reticulum stress. Clin Exp Dermatol 41(1):64. https://doi.org/10.1111/ced.12664 

    상세보기 crossref

  28. Br J Dermatol F Meredith 170 565 2013 10.1111/bjd.12669 Meredith F, Abbott R (2013) Vitiligo: an evidence-based update. Report of the 13th Evidence Based Update Meeting, 23 May 2013, Loughborough, U.K. Br J Dermatol 170:565-570 

    상세보기 crossref

  29. Hautarzt M Meurer 67 249 2016 10.1007/s00105-016-3768-4 Meurer M, Schild M (2016) Therapie der Vitiligo. Hautarzt 67:249-264 

    상세보기 crossref

  30. Int J Dermatol D Parsad 10 753 1993 Parsad D, Gupta S (1993) Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading vitiligo. Int J Dermatol 10:753-757 

  31. Clin Exp Dermatol D Parsad 28 285 2003 10.1046/j.1365-2230.2003.01207.x Parsad D, Pandhi R, Juneja A (2003) Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 28:285-287 

    상세보기 crossref

  32. J Am Acad Dermatol JR Porter 22 221 1990 10.1016/0190-9622(90)70028-G Porter JR, Beuf AH, Lerner AB, Nordlund JJ (1990) The effect of vitiligo on sexual relationships. J Am Acad Dermatol 22:221-222 

    상세보기 crossref

  33. J Dermatolog Treat M Radmanesh 17 151 2006 10.1080/09546630600791442 Radmanesh M, Saedi K (2006) The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 17:151-153 

    상세보기 crossref

  34. Am J Pathol S Rana 178 2783 2011 10.1016/j.ajpath.2011.02.016 Rana S, Rogers LJ, Halliday GM (2011) Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am J Pathol 178:2783-2791 

    상세보기 crossref

  35. Med M Rashigi 21 343 2015 10.3978/j.issn.2305-5839.2015.11.36 Rashigi M, Harris JE (2015) Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Trans Med 21:343-348. https://doi.org/10.3978/j.issn.2305-5839.2015.11.36 

    crossref

  36. Indian J Dermatol Venereol Leprol N Rath 74 357 2008 10.4103/0378-6323.42905 Rath N, Kar HK, Sabhnani S (2008) An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 74:357-360 

    상세보기 crossref

  37. J Invest Dermatol JM Richmond 137 350 2017 10.1016/j.jid.2016.09.016 Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE (2017) Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol 137:350-358 

    상세보기 crossref

  38. Dermatology D Rigopoulos 215 84 2007 10.1159/000102044 Rigopoulos D, Gregoriou S, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D (2007) Etanercept in the treatment of vitiligo. Dermatology 215:84-85 

    상세보기 crossref

  39. J Am Acad Dermatol B Rothstein 76 54 2017 10.1016/j.jaad.2017.02.049 Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D (2017) Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 76:54-1060 

    상세보기 crossref

  40. Clin Exp Immunol A Ruiz-Arguelles 174 229 2013 10.1111/cei.12168 Ruiz-Arguelles A, García-Carrasco M, Jimenez-Brito G, Sánchez-Sosa S, Pérez-Romano B, Garcés-Eisele J, Camacho-Alarcón C, Reyes-Núñez V, Sandoval-Cruz M, Mendoza-Pinto C, López-Colombo A (2013) Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol 174:229-236 

    상세보기 crossref

  41. Science SM Russell 270 797 1995 10.1126/science.270.5237.797 Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O’Shea JJ, Leonard WJ (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270:797-800 

    상세보기 crossref

  42. Indian J Dermatol LN Sangma 60 142 2015 10.4103/0019-5154.152508 Sangma LN, Nath J, Bhagabati D (2015) Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from North-East India. Indian J Dermatol 60:142-146 

    상세보기 crossref

  43. Hautarzt M Schild 67 173 2016 10.1007/s00105-015-3751-5 Schild M, Meurer M (2016) Vitiligo. Klinik und Pathogenese. Hautarzt 67:173-186 

    상세보기 crossref

  44. Dermatology H Singh 231 286 2015 10.1159/000433424 Singh H, Kumaran MS, Bains A, Parsad D (2015) A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology 231:286-290 

    상세보기 crossref

  45. Autoimmun Rev R Speeckaert 16 937 2017 10.1016/j.autrev.2017.07.005 Speeckaert R, Speeckaert M, De Schepper S, van Geel N (2017) Biomarkers of disese activity in vitiligo: a systematic review. Autoimmun Rev 16:937-945 

    상세보기 crossref

  46. BMC Complement Altern Med O Sczcurko 11 21 2011 10.1186/1472-6882-11-21 Sczcurko O, Shear N, Taddio A, Boon H (2011) Ginkgo biloba for the treatment of vitiligo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 11:21-25 

    상세보기 crossref

  47. J Am Acad Dermatol R Shreberk-Hassidim 76 745 2017 10.1016/j.jaad.2016.12.004 Shreberk-Hassidim R, Ramot Y, Zlotogorski A (2017) A Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol 76:745-753 

    상세보기 crossref

  48. Curr Opin Immunol JP Strassner 43 81 2016 10.1016/j.coi.2016.09.008 Strassner JP, Harris JE (2016) Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol 43:81-88 

    상세보기 crossref

  49. Pigment Cell Res A Taïeb 20 27 2007 10.1111/j.1600-0749.2006.00355.x Taïeb A, Picardo M, VETF Members (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20:27-35 

    상세보기 crossref

  50. Br J Dermatol A Taïeb 168 5 2013 10.1111/j.1365-2133.2012.11197.x Taïeb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M (2013) Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 168:5-19 

    상세보기 crossref

  51. Pigment Cell Melanoma Res N Geel van 30 436 2017 10.1111/pcmr.12593 van Geel N, Boniface K, Seneschal J, Jacquemin C, Speeckaert R, Wolkerstorfer A, Bekkenk M, Lommerts JE, Hamzavi I, Pandya A, Eleftheriadou V, Ezzedine K, Giannarelli D, Gnarra M, Sperduti I, Prinsen C, Harris J, Taieb A, Picardo M (2017) Meeting report: vitiligo global issues consensus conference workshop “outcome measurement instruments” and vitiligo international symposium, Rome, Nov 30-Dec 3rd. Pigment Cell Melanoma Res 30:436-443 

    상세보기 crossref

  52. Br J Dermatol XX Wang 174 6 1318 2016 10.1111/bjd.14416 Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH (2016) Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol 174(6):1318-1326 

    상세보기 crossref

  53. Br J Dermatol KC Webb 173 641 2015 10.1111/bjd.14016 Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC (2015) Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol 173:641-650 

    상세보기 crossref

  54. Nat Rev Rheumatol KL Winthrop 13 234 2017 10.1038/nrrheum.2017.23 Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:234-243 

    상세보기 crossref

  55. Cochrane Database Syst Rev ME Whitton 2015 10.1002/14651858.CD003263.pub5 Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, Ezzedine K (2015) Interventions for vitiligo. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003263.pub5 

    상세보기 crossref

  56. Br J Dermatol CS Wu 156 122 2007 10.1111/j.1365-2133.2006.07584.x Wu CS, Lan CC, Wang LF, Chen GS, Wu CS, Yu HS (2007) Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 156:122-129 

    상세보기 crossref

  57. Exp Dermatol CS Wu 13 755 2004 10.1111/j.0906-6705.2004.00221.x Wu CS, Yu CL, Wu CS, Lan CC, Yu HS (2004) Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 13:755-763 

    상세보기 crossref

  58. Arch Dermatol SS Yones 143 578 2007 10.1001/archderm.143.5.578 Yones SS, Palmer RA, Garibaldinos TM, Hawk JL (2007) Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 143:578-584 

    상세보기 crossref

관련 콘텐츠

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로